Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)

References

• Sondermann W, Schreiber A, Körber A, et al. Psychosocial burden and body mass index are associated with dermatology-related quality of life in psoriasis patients. Eur J Dermatol. 2020;30(2):140–147. doi:10.1684/ejd.2020.3755
   PubMed Web of Science ®Google Scholar
• Sahin E, Hawro M, Weller K, et al. Prevalence and factors associated with sleep disturbance in adult patients with psoriasis. J Eur Acad Dermatol Venereol. 2022;36(5):688–697. doi:10.1111/jdv.17917
   PubMed Web of Science ®Google Scholar
• Schadler ED, Ortel B, Mehlis SL. Biologics for the primary care physician: review and treatment of psoriasis. Disease-A-Month. 2019;65(3):51–90. doi:10.1016/j.disamonth.2018.06.001
   PubMed Web of Science ®Google Scholar
• Nazik H, Nazik S, Gul FC. Body image, self-esteem, and quality of life in patients with psoriasis. Indian Derm. 2017;8(5):343.
   PubMedGoogle Scholar
• LoCasale RJ, Pashos CL, Gutierrez B, et al. Bridging the gap between RCTs and RWE through endpoint selection. Ther Innov Regul Sci. 2021;55(1):90–96. doi:10.1007/s43441-020-00193-5
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris–Part 1: treatment and monitoring recommendations. J Eur Acad Derm Venereol. 2020;34(11):2461–2498. doi:10.1111/jdv.16915
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris–Part 2: specific clinical and comorbid situations. J Eur Acad Derm Venereol. 2021;35(2):281–317. doi:10.1111/jdv.16926
   PubMed Web of Science ®Google Scholar
• Gorelick J, Shrom D, Sikand K, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther. 2019;9(4):785–797. doi:10.1007/s13555-019-00334-1
   Web of Science ®Google Scholar
• Maul JT, Navarini AA, Sommer R, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis–a lesson for practice. J Eur Acad Derm Venereol. 2019;33(4):700–708. doi:10.1111/jdv.15324
   PubMed Web of Science ®Google Scholar
• Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2018;17(3):247–250.
   PubMed Web of Science ®Google Scholar
• Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses. Dermatol Ther. 2020;10(1):73–86. doi:10.1007/s13555-019-00337-y
   PubMed Web of Science ®Google Scholar
• Maul JT, Augustin M, Sorbe C, et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two‐country, multicentre, prospective, noninterventional registry study. Br J Dermatol. 2021;185(6):1160–1168. doi:10.1111/bjd.20387
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp K, Gottlieb A, et al. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. Br J Dermatol. 2020;182(6):1348–1358. doi:10.1111/bjd.18851
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Soliman AM, Betts KA, et al. Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther. 2021;11(3):885–905. doi:10.1007/s13555-021-00511-1
   PubMed Web of Science ®Google Scholar
• Pinter A, Puig L, Schäkel K, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087–2100. doi:10.1111/jdv.18376
   PubMed Web of Science ®Google Scholar
• European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP); 2018. Available from: https://www.encepp.eu/encepp/viewResource.htm?id=25115. Accessed June 1, 2023.
   Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--A simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x
   PubMed Web of Science ®Google Scholar
• Kimball AB, Naegeli AN, Edson‐Heredia E, et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis. Br J Dermatol. 2016;175(1):157–162. doi:10.1111/bjd.14464
   PubMed Web of Science ®Google Scholar
• Mathias SD, Feldman SR, Crosby RD, Colwell HH, McQuarrie K, Han C. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary. J Dermatol Treat. 2016;27(4):322–327. doi:10.3109/09546634.2015.1114567
   PubMed Web of Science ®Google Scholar
• Reich A, Pinter A, Maul J-T, et al. Speed of clinical improvement in the real-world setting from Patient-Reported Psoriasis Symptoms and Signs Diary (PSSD): secondary outcomes from the Psoriasis Study of Health Outcomes (PSoHO) through 12 weeks. J Eur Acad Dermatol Venereol. 2023;37(9):1825–1840. doi:10.1111/jdv.19161
   PubMedGoogle Scholar
• Lynde C, Riedl E, Maul JT, et al. Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at Week 12 from the PSoHO Study in a real-world setting. Adv Ther. 2023;40(3):869–886. doi:10.1007/s12325-022-02379-9
   PubMed Web of Science ®Google Scholar
• Piaserico S, Riedl E, Pavlovsky L, et al. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO). Front Med. 2023;10:1257. doi:10.3389/fmed.2023.1185523
   Web of Science ®Google Scholar
• Augustin M, Schuster C, Mert C, Nast A. The value of indirect comparisons of systemic biologics for psoriasis: interpretation of efficacy findings. Dermatol Ther. 2022;12(8):1711–1727. doi:10.1007/s13555-022-00765-3
   Web of Science ®Google Scholar
• Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047–1058. doi:10.1111/bjd.19509
   PubMed Web of Science ®Google Scholar
• Graier T, Salmhofer W, Jonak C, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021;184(6):1094–1105. doi:10.1111/bjd.19701
   PubMed Web of Science ®Google Scholar
• van Muijen ME, Thomas SE, Groenewoud H, et al. Direct comparison of real-world effectiveness of biologics for psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a prospective multicentre cohort. Acta Derm Venereol. 2022;102:adv00711. doi:10.2340/actadv.v102.206
   PubMed Web of Science ®Google Scholar
• Caldarola G, Chiricozzi A, Megna M, et al. Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert Opin Bio Ther. 2023;23(4):365–370. doi:10.1080/14712598.2023.2193288
   PubMed Web of Science ®Google Scholar
• Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatol Treat. 2015;26(3):235–239. doi:10.3109/09546634.2014.943687
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170. doi:10.3390/jcm9072170
   PubMed Web of Science ®Google Scholar
• Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real‐life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6):e13964. doi:10.1111/dth.13964
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of interleukin (IL)‑17 and IL‑23 inhibitors for the treatment of psoriasis: a retrospective multi‑country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904. doi:10.1007/s40257-022-00722-y
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Reich K, Foley P, et al. Improvement in patient-reported outcomes (dermatology life quality index and the psoriasis symptoms and signs diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the Phase III VOYAGE 1 and VOYAGE 2 studies. Am J Clin Dermatol. 2019;20(1):155–164. doi:10.1007/s40257-018-0396-z
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123. doi:10.1111/bjd.15750
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the Phase III, double-blind, placebo-and active comparator–controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. doi:10.1016/j.jaad.2016.11.042
   PubMed Web of Science ®Google Scholar
• Proietti I, Bernardini N, Skroza N, et al. PSSD and biologic therapy: real-life data in 417 patients with moderate to severe psoriasis. Rev Recent Clin Trials. 2022;17(3):171–176. doi:10.2174/1574887117666220623161751
   Web of Science ®Google Scholar
• Reich A, Reed C, Schuster C, Robert C, Treuer T, Lubrano E. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021. J Dermatol Treat. 2023;34(1):2160196. doi:10.1080/09546634.2022.2160196
   PubMed Web of Science ®Google Scholar
• Khattri S, Goldblum O, Solotkin K, et al. Early onset of clinical improvement with ixekizumab in a randomized, open-label study of patients with moderate-to-severe plaque psoriasis. J Clin Aesthet Dermatol. 2018;11(5):33–37.
   PubMedGoogle Scholar